Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer

A study by the Italian Trials in Medical Oncology Group

A. Di Leo, E. Bajetta, R. Buzzoni, A. M. Bochicchio, L. Nole, F. Biganzoli, M. D'Aprile, E. Veltri, G. Comella, E. Aitini, A. Di Lallo, M. Santini, S. Luccarelli, A. R. Bian

Research output: Contribution to journalArticle

4 Citations (Scopus)

Abstract

The evaluation of drug efficacy in patients with advanced prostatic cancer who have progressed to hormonal therapy is difficult, although palliation of the pain related to bone involvement still represents an important endpoint. In this study, epirubicin (EpiADM) plus medroxyprogesterone acetate (MPA) were given to advanced prostatic cancer patients with symptomatic bone involvement who had progressed to hormonal therapy. EpiADM was administered at a dose of 30 mg/m2 i.v. weekly and MPA at a daily dose of 1,000 mg p.o. for the first month and 500 mg thereafter. Fifty-four patients entered the trial, all of whom were evaluable. Amelioration of pain and a ≥50% reduction in analgesic intake were observed in 52% of cases, with a mean duration of 4 months. Of the 28 responsive patients, 26 had already received two lines of hormonal therapy or were resistant to first-line therapy. Of the 23 patients with measurable lesions, 6 obtained a ≥50% tumor shrinkage at these sites. The treatment was well tolerated, and no cardiac toxicity was observed up to a total cumulative EpiADM dose of 660 mg/m2. In conclusion, this regimen seems to have a palliative effect in patients with advanced prostatic cancer who have progressed to hormonal therapy, and it is feasible in an outpatient setting.

Original languageEnglish
Pages (from-to)239-244
Number of pages6
JournalAmerican Journal of Clinical Oncology: Cancer Clinical Trials
Volume18
Issue number3
Publication statusPublished - 1995

Fingerprint

Medroxyprogesterone
Epirubicin
Medical Oncology
Prostatic Neoplasms
Medroxyprogesterone Acetate
Therapeutics
Bone and Bones
Pain
Drug Evaluation
Analgesics
Outpatients

Keywords

  • Advanced prostatic cancer
  • Response criteria
  • Second-line therapy

ASJC Scopus subject areas

  • Cancer Research
  • Oncology

Cite this

Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer : A study by the Italian Trials in Medical Oncology Group. / Di Leo, A.; Bajetta, E.; Buzzoni, R.; Bochicchio, A. M.; Nole, L.; Biganzoli, F.; D'Aprile, M.; Veltri, E.; Comella, G.; Aitini, E.; Di Lallo, A.; Santini, M.; Luccarelli, S.; Bian, A. R.

In: American Journal of Clinical Oncology: Cancer Clinical Trials, Vol. 18, No. 3, 1995, p. 239-244.

Research output: Contribution to journalArticle

Di Leo, A, Bajetta, E, Buzzoni, R, Bochicchio, AM, Nole, L, Biganzoli, F, D'Aprile, M, Veltri, E, Comella, G, Aitini, E, Di Lallo, A, Santini, M, Luccarelli, S & Bian, AR 1995, 'Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer: A study by the Italian Trials in Medical Oncology Group', American Journal of Clinical Oncology: Cancer Clinical Trials, vol. 18, no. 3, pp. 239-244.
Di Leo, A. ; Bajetta, E. ; Buzzoni, R. ; Bochicchio, A. M. ; Nole, L. ; Biganzoli, F. ; D'Aprile, M. ; Veltri, E. ; Comella, G. ; Aitini, E. ; Di Lallo, A. ; Santini, M. ; Luccarelli, S. ; Bian, A. R. / Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer : A study by the Italian Trials in Medical Oncology Group. In: American Journal of Clinical Oncology: Cancer Clinical Trials. 1995 ; Vol. 18, No. 3. pp. 239-244.
@article{81bc9eb16ad24bb998968b845af01066,
title = "Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer: A study by the Italian Trials in Medical Oncology Group",
abstract = "The evaluation of drug efficacy in patients with advanced prostatic cancer who have progressed to hormonal therapy is difficult, although palliation of the pain related to bone involvement still represents an important endpoint. In this study, epirubicin (EpiADM) plus medroxyprogesterone acetate (MPA) were given to advanced prostatic cancer patients with symptomatic bone involvement who had progressed to hormonal therapy. EpiADM was administered at a dose of 30 mg/m2 i.v. weekly and MPA at a daily dose of 1,000 mg p.o. for the first month and 500 mg thereafter. Fifty-four patients entered the trial, all of whom were evaluable. Amelioration of pain and a ≥50{\%} reduction in analgesic intake were observed in 52{\%} of cases, with a mean duration of 4 months. Of the 28 responsive patients, 26 had already received two lines of hormonal therapy or were resistant to first-line therapy. Of the 23 patients with measurable lesions, 6 obtained a ≥50{\%} tumor shrinkage at these sites. The treatment was well tolerated, and no cardiac toxicity was observed up to a total cumulative EpiADM dose of 660 mg/m2. In conclusion, this regimen seems to have a palliative effect in patients with advanced prostatic cancer who have progressed to hormonal therapy, and it is feasible in an outpatient setting.",
keywords = "Advanced prostatic cancer, Response criteria, Second-line therapy",
author = "{Di Leo}, A. and E. Bajetta and R. Buzzoni and Bochicchio, {A. M.} and L. Nole and F. Biganzoli and M. D'Aprile and E. Veltri and G. Comella and E. Aitini and {Di Lallo}, A. and M. Santini and S. Luccarelli and Bian, {A. R.}",
year = "1995",
language = "English",
volume = "18",
pages = "239--244",
journal = "American Journal of Clinical Oncology",
issn = "0277-3732",
publisher = "Lippincott Williams and Wilkins",
number = "3",

}

TY - JOUR

T1 - Epirubicin plus medroxyprogesterone as second-line treatment of advanced prostatic cancer

T2 - A study by the Italian Trials in Medical Oncology Group

AU - Di Leo, A.

AU - Bajetta, E.

AU - Buzzoni, R.

AU - Bochicchio, A. M.

AU - Nole, L.

AU - Biganzoli, F.

AU - D'Aprile, M.

AU - Veltri, E.

AU - Comella, G.

AU - Aitini, E.

AU - Di Lallo, A.

AU - Santini, M.

AU - Luccarelli, S.

AU - Bian, A. R.

PY - 1995

Y1 - 1995

N2 - The evaluation of drug efficacy in patients with advanced prostatic cancer who have progressed to hormonal therapy is difficult, although palliation of the pain related to bone involvement still represents an important endpoint. In this study, epirubicin (EpiADM) plus medroxyprogesterone acetate (MPA) were given to advanced prostatic cancer patients with symptomatic bone involvement who had progressed to hormonal therapy. EpiADM was administered at a dose of 30 mg/m2 i.v. weekly and MPA at a daily dose of 1,000 mg p.o. for the first month and 500 mg thereafter. Fifty-four patients entered the trial, all of whom were evaluable. Amelioration of pain and a ≥50% reduction in analgesic intake were observed in 52% of cases, with a mean duration of 4 months. Of the 28 responsive patients, 26 had already received two lines of hormonal therapy or were resistant to first-line therapy. Of the 23 patients with measurable lesions, 6 obtained a ≥50% tumor shrinkage at these sites. The treatment was well tolerated, and no cardiac toxicity was observed up to a total cumulative EpiADM dose of 660 mg/m2. In conclusion, this regimen seems to have a palliative effect in patients with advanced prostatic cancer who have progressed to hormonal therapy, and it is feasible in an outpatient setting.

AB - The evaluation of drug efficacy in patients with advanced prostatic cancer who have progressed to hormonal therapy is difficult, although palliation of the pain related to bone involvement still represents an important endpoint. In this study, epirubicin (EpiADM) plus medroxyprogesterone acetate (MPA) were given to advanced prostatic cancer patients with symptomatic bone involvement who had progressed to hormonal therapy. EpiADM was administered at a dose of 30 mg/m2 i.v. weekly and MPA at a daily dose of 1,000 mg p.o. for the first month and 500 mg thereafter. Fifty-four patients entered the trial, all of whom were evaluable. Amelioration of pain and a ≥50% reduction in analgesic intake were observed in 52% of cases, with a mean duration of 4 months. Of the 28 responsive patients, 26 had already received two lines of hormonal therapy or were resistant to first-line therapy. Of the 23 patients with measurable lesions, 6 obtained a ≥50% tumor shrinkage at these sites. The treatment was well tolerated, and no cardiac toxicity was observed up to a total cumulative EpiADM dose of 660 mg/m2. In conclusion, this regimen seems to have a palliative effect in patients with advanced prostatic cancer who have progressed to hormonal therapy, and it is feasible in an outpatient setting.

KW - Advanced prostatic cancer

KW - Response criteria

KW - Second-line therapy

UR - http://www.scopus.com/inward/record.url?scp=0029069066&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029069066&partnerID=8YFLogxK

M3 - Article

VL - 18

SP - 239

EP - 244

JO - American Journal of Clinical Oncology

JF - American Journal of Clinical Oncology

SN - 0277-3732

IS - 3

ER -